 Peroxisome Proliferator-Activated Receptors
"Peroxisome Proliferator-Activated Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
TRANSCRIPTION FACTORS that are activated by ligands and heterodimerize with RETINOID X RECEPTORS and bind to peroxisome proliferator response elements in the promoter regions of target genes.
| Descriptor ID |
D047492
|
| MeSH Number(s) |
D12.776.826.239 D12.776.930.705
|
| Concept/Terms |
Peroxisome Proliferator-Activated Receptors- Peroxisome Proliferator-Activated Receptors
- Peroxisome Proliferator Activated Receptors
- Proliferator-Activated Receptors, Peroxisome
- Receptors, Peroxisome Proliferator-Activated
- PPAR
|
Below are MeSH descriptors whose meaning is more general than "Peroxisome Proliferator-Activated Receptors".
Below are MeSH descriptors whose meaning is more specific than "Peroxisome Proliferator-Activated Receptors".
This graph shows the total number of publications written about "Peroxisome Proliferator-Activated Receptors" by people in this website by year, and whether "Peroxisome Proliferator-Activated Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2013 | 1 | 0 | 1 | | 2014 | 0 | 2 | 2 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Peroxisome Proliferator-Activated Receptors" by people in Profiles.
-
Yao L, Zhang X, Huang C, Cai Y, Wan CC. The Effect of Citrus aurantium on Non-Small-Cell Lung Cancer: A Research Based on Network and Experimental Pharmacology. Biomed Res Int. 2023; 2023:6407588.
-
Liggett JR, Kang J, Ranjit S, Rodriguez O, Loh K, Patil D, Cui Y, Duttargi A, Nguyen S, He B, Lee Y, Oza K, Frank BS, Kwon D, Li HH, Kallakury B, Libby A, Levi M, Robson SC, Fishbein TM, Cui W, Albanese C, Khan K, Kroemer A. Oral N-acetylcysteine decreases IFN-? production and ameliorates ischemia-reperfusion injury in steatotic livers. Front Immunol. 2022; 13:898799.
-
Huot JR, Pin F, Chatterjee R, Bonetto A. PGC1a overexpression preserves muscle mass and function in cisplatin-induced cachexia. J Cachexia Sarcopenia Muscle. 2022 10; 13(5):2480-2491.
-
Kelly AC, J Rosario F, Chan J, Cox LA, Powell TL, Jansson T. Transcriptomic responses are sex-dependent in the skeletal muscle and liver in offspring of obese mice. Am J Physiol Endocrinol Metab. 2022 Oct 01; 323(4):E336-E353.
-
Loving BA, Tang M, Neal MC, Gorkhali S, Murphy R, Eckel RH, Bruce KD. Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation. Cells. 2021 01 20; 10(2).
-
Libby AE, Jones B, Lopez-Santiago I, Rowland E, Levi M. Nuclear receptors in the kidney during health and disease. Mol Aspects Med. 2021 04; 78:100935.
-
Morici N, Savonitto S, Ponticelli C, Schrieks IC, Nozza A, Cosentino F, Stähli BE, Perrone Filardi P, Schwartz GG, Mellbin L, Lincoff AM, Tardif JC, Grobbee DE. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. Am J Med. 2017 09; 130(9):1068-1075.
-
Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med. 2016 Apr 07; 374(14):1321-31.
-
Gusenleitner D, Auerbach SS, Melia T, Gómez HF, Sherr DH, Monti S. Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action. PLoS One. 2014; 9(7):e102579.
-
Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, Malmberg K, Wedel H, Buse JB, Henry RR, Weichert A, Cannata R, Svensson A, Volz D, Grobbee DE. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014 Apr 16; 311(15):1515-25.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|